<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073905</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 44/02</org_study_id>
    <secondary_id>EU-20322</secondary_id>
    <nct_id>NCT00073905</nct_id>
  </id_info>
  <brief_title>Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer</brief_title>
  <official_title>Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Palliative chemotherapy&#xD;
      may improve the quality of life in patients who have locally advanced or metastatic biliary&#xD;
      tract cancer and may help them live more comfortably.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of adjuvant capecitabine and gemcitabine&#xD;
      in improving quality of life in patients who have locally advanced or metastatic biliary&#xD;
      tract cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the ability of palliative capecitabine and gemcitabine to maintain or improve&#xD;
           tumor-related symptoms (after treatable biliary duct obstruction has been relieved) as&#xD;
           measured by the clinical benefit response in patients with locally advanced or&#xD;
           metastatic biliary tract cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the clinical benefit response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to and duration of clinical benefit response in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the objective response and time to progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the adverse events in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and oral capecitabine twice&#xD;
      daily on days 1-14 (28 total doses). Treatment repeats every 21 days for 8 courses in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients responding to treatment may&#xD;
      receive additional courses at the discretion of the investigator.&#xD;
&#xD;
      Quality of life is assessed at baseline, weekly during weeks 2-9 (courses 1-3), and then&#xD;
      before each administration of gemcitabine.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-44 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of palliative capecitabine and gemcitabine</measure>
    <time_frame>3 months</time_frame>
    <description>Determine the ability of palliative capecitabine and gemcitabine to maintain or improve tumor-related symptoms (after treatable biliary duct obstruction has been relieved) as measured by the clinical benefit response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit response alone as measured after 3 courses</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine plus Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine plus gemcitabine</intervention_name>
    <description>capecitabine plus gemcitabine</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed biliary tract cancer&#xD;
&#xD;
               -  Locally advanced, unresectable, or metastatic disease&#xD;
&#xD;
          -  Metastatic adenocarcinoma with clinical documentation of gallbladder or bile tree&#xD;
             involvement with no evidence of another primary adenocarcinoma allowed&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  Treatable biliary duct obstruction must be relieved by either internal endoscopic&#xD;
             drainage/stenting or palliative bypass surgery before study entry&#xD;
&#xD;
          -  Symptomatic biliary tract cancer and has at least 1 of the following:&#xD;
&#xD;
               -  Karnofsky 60-80%&#xD;
&#xD;
               -  Baseline analgesic consumption at least 10 mg of morphine equivalents per day&#xD;
&#xD;
               -  Baseline pain intensity score of at least 20 mm out of a possible 100 mm&#xD;
&#xD;
          -  No prior or concurrent CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 4 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
          -  AST and ALT no greater than 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled cardiovascular disease&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to ingest oral medication&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  No intractable nausea and/or vomiting&#xD;
&#xD;
          -  No partial small bowel obstruction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 year after study&#xD;
             participation&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No known hypersensitivity to fluorouracil&#xD;
&#xD;
          -  No known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  No definitive contraindication to corticosteroids&#xD;
&#xD;
          -  No prior significant neurologic or psychiatric disorders (e.g., psychotic disorders,&#xD;
             dementia, or seizures) that would preclude understanding or providing informed consent&#xD;
&#xD;
          -  No prior severe reaction to fluoropyrimidine therapy&#xD;
&#xD;
          -  No psychiatric disorder, cognitive dysfunction, or language problem that would&#xD;
             preclude filling out the quality of life questionnaire or patient diary&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             adequately treated carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for advanced/metastatic disease&#xD;
&#xD;
          -  No prior palliative chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent megestrol&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
               -  Treatment of a single painful lesion allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior Whipple procedure allowed&#xD;
&#xD;
          -  Prior duodenal bypass allowed&#xD;
&#xD;
          -  No concurrent endoscopic or external biliary drainage as a consequence of progressive&#xD;
             malignant bile duct obstruction&#xD;
&#xD;
               -  Drainage as a consequence of nonmalignant bile duct obstruction allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior treatment within a clinical study&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent sorivudine or its chemically-related analogues (e.g., lamivudine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koeberle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Gerber D, Dietrich D, Koeberle D, et al.: Clinical benefit and quality of life in patients with advanced biliary tract cancer receiving gemcitabine plus capecitabine (GemCap): results from a multicenter phase II trial (SAKK 44/02). [Abstract] J Clin Oncol 26 (Suppl 15): A-15531, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.</citation>
    <PMID>18669455</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>June 2, 2012</last_update_submitted>
  <last_update_submitted_qc>June 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>adenocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>pain</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

